<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552590</url>
  </required_header>
  <id_info>
    <org_study_id>156-KOB-1101i</org_study_id>
    <nct_id>NCT01552590</nct_id>
  </id_info>
  <brief_title>Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites</brief_title>
  <acronym>ECF</acronym>
  <official_title>Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy of a 2-week course of tolvaptan in improving serum
      sodium and the excretion of extracellular fluid in liver cirrhotic patients with ascites and
      hyponatremia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Na</measure>
    <time_frame>2 weeks (Baseline, Day 14)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCM (body composition monitoring)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite endpoint of ascites worsening</measure>
    <time_frame>in case</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Na normalization rate</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry</measure>
    <time_frame>7 days</time_frame>
    <description>Total protein, Albumin, ALP, ALT, AST, r-GT, BUN, Creatinine, Glucose, Cl, K, Na, Ca, Total bilirubin, Uric acid), Hematology (WBC count, Hemoglobin, Hematocrit, Platelets, Serum osm, NT pro-BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>7 days</time_frame>
    <description>HEENT, Thorax, Abdomen, Urogenital, Extremities, Neurological, Skin and Mucosae</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood coagulation</measure>
    <time_frame>7 days</time_frame>
    <description>PT, INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>7 days</time_frame>
    <description>Protein, pH, Glucose, Blood, Bilirubin, Urobilinogen, Random urine Na/K, Urine osm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Hyponatremia and Extracellular Fluid in Cirrhotic</condition>
  <arm_group>
    <arm_group_label>Tolvaptan, Tablet, QD, 2 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Tablet, QD, 2 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <arm_group_label>Tolvaptan, Tablet, QD, 2 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo, Tablet, QD, 2 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged ≥ 20 years

          2. Subjects who have been diagnosed with hyponatremia [serum sodium &lt; 125 mEq/L or less
             marked hyponatremia that is symptomatic and has resisted correction with fluid
             restriction]

          3. Subjects who have been diagnosed with an ascites on the abdominal ultrasound.

          4. Subjects who have diagnosed with cirrhosis.

          5. Subject or their legally acceptable representatives are able to provide informed
             consent/assent.

        Exclusion Criteria:

          1. Subject who has ascites by other causes (Tbc, CHF, malignancy, or renal disease) acute
             severe hyponatemia : Serum Na level &lt; 120 mmol/L and Doubt of symptom caused by
             hyponatremia and the case which should raise serum Na level urgently based on the
             investigator's judgment international normalized ratio (INR) &gt;3.0 serum sodium ≥135
             mmol/L serum potassium &gt; 5.5 mmol/L Creatinine ≥ 2.0 mg/dL Hepatorenal syndrome
             defined as 'New International Ascites Club's diagnostic criteria' systolic arterial
             pressure of &lt; 80 mmHg recent myocardial infarction (&lt; 6 month) spontaneous bacterial
             peritonitis gastrointestinal bleed ( ≤7 days from randomization) ongoing hepatic
             encephalopathy of &gt; grade1 known hepatocellular carcinoma intractable ascites

          2. Subject who requiring urgent intervention to raise serum sodium acutely

          3. Subject who are unable to sense or to respond appropriately to thirst

          4. Subject with hypovolemic hyponatremia

          5. Subject who should take strong CYP3A inhibitors (clarithromycin, ketoconazole,
             itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and
             telithromycin)

          6. Subject who are anuric as no benefit is expected

          7. Subject who has genetic defects such as galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption

          8. Subject who has fluid depletion

          9. Female subjects who are pregnant or lactating

         10. Subject judged by the investigator to be inappropriate for inclusion in the trial for
             any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YoungJin Choi</last_name>
    <phone>+82232879255</phone>
    <email>youngjin@otsuka.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym Univ. Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KiTae Suk, Assistant professor</last_name>
    </contact>
    <investigator>
      <last_name>KiTae Suk, Assistant professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang Univ. Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungSeok Kim, Associate professor</last_name>
    </contact>
    <investigator>
      <last_name>YoungSeok Kim, Associate professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SoonKoo Baik, Professor</last_name>
    </contact>
    <investigator>
      <last_name>SoonKoo Baik, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

